BeiGene Releases 2021 Environmental, Social and Governance (ESG) Report

"At BeiGene, we're committed to being a transformative company that brings access to more patients around the world," said John V.

In the past year, BeiGene officially established the ESG functional department and launched a new ESG strategic framework with the theme of " Change the future ?" , focusing on five key focus areas to meet the needs of different stakeholders

1. Advancing Global Health: Innovative Medicines; Access and Affordability
2. Empowering Employees: Diversity, Equity and Inclusion (DEI); Employee Engagement and Wellbeing
3. Sustainable Innovation: Climate Change; Product Stewardship
4. Supporting Communities: Patient Engagement and Advocacy; Charitable Giving and Volunteering
5. Responsible Operations: Business Ethics and Integrity; Responsible Sourcing

Christine Riley Miller, head of ESG at BeiGene, said: "While our ESG is still in the early stages of development, I am proud of the progress the company has made over the past year

BeiGene’s 2021 ESG Report is based on the Global Reporting Initiative (GRI) standards.

• The company has nearly 50 commercial products and clinical candidates in clinical development; more than 30 pivotal or potential registration trials are underway in more than 45 countries and regions; more than 50 preclinical research projects, of which nearly 50% Possess "first-in-class" or "best-in-class" potential;
• In China, we have 16 approved commercial products.
  
  

  BeiGene is a science-based global biotechnology company focused on developing innovative, affordable medicines designed to improve outcomes and improve access to medicines for patients around the world

  
  

  Forward-Looking Statements 

  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene ESG's plans, commitments, retaliations and objectives.